PPD Inc. no longer trades as an independent public equity on stock exchanges, as the clinical research organization was acquired by Thermo Fisher Scientific in a multi-billion-dollar cash transaction. Under the terms of the final acquisition agreement, public shareholders received $47.50 per share in cash, after which the company was fully integrated into Thermo Fisher's laboratory products and pharmaceutical services division.